Epidemiologic Field Studies

BCDDP：乳腺癌检测示范项目随访研究（01030）。这项研究跟踪了大约6万名前乳腺癌示范项目（BCDDP）的参与者。目前的分析包括各种队列财团汇集项目。胃癌：山东临朐抑制胃癌前病变的随机多干预试验（00446）。我们从中国农村一项为期8年的试验中收集了15年的随访数据，以确定三种治疗方法中的任何一种是否会影响胃癌的发病率或特定的死亡原因。治疗是长期的维生素（C，E和硒）补充剂和大蒜补充剂，从1995年到2003年，并在1995年给予阿莫西林/奥美拉唑一次。2012年发表的一篇论文显示，阿莫西林/奥美拉唑治疗在15年内将胃癌发病率降低了39%。我们检查了亚组，并确定在研究开始时抗生素治疗对老年人和晚期胃癌前病变患者有效，尽管幽门螺杆菌被认为作用于胃癌发生的早期阶段。因此，抗生素治疗可以广泛应用于预防胃癌，而不必局限于年轻人或组织病理学轻度的人。这项工作于2014年出版。 炎症性乳腺癌（IBC）病例对照研究（00314）该病例对照研究包括北非5个中心（突尼斯1个中心、埃及2个中心和摩洛哥2个中心）累积的约250例IBC病例。纳入两个对照组：1）250例非IBC乳腺癌病例; 2）250例访视对照（不包括一级亲属），随机选择研究医院的女性住院患者（不包括乳腺癌、卵巢癌、子宫内膜癌和鼻咽癌患者）。这项研究包括问卷调查，人体测量，唾液收集，

BCDDP: Breast Cancer Detection Demonstration Project follow-up study (01030). This study follows about 60,000 former participants in the Breast Cancer Demonstration Project (BCDDP). Current analyses include a variety of cohort consortium pooling projects. Gastric cancer: Randomized multi-intervention trial to inhibit precancerous gastric lesions in Linqu, Shandong Province (00446). We gathered fifteen year follow-up data from an 8-year trial in rural China to determine whether any of three treatments would affect gastric cancer incidence or specific causes of mortality. The treatments were long-term vitamin (C, E, and selenium) supplementation and garlic supplementation, given from 1995 to 2003, and one time administration of amoxicillin/omeprazole given in 1995. A paper published in 2012 showed that amoxicillin/omeprazole treatment reduced gastric cancer incidence by 39% over a fifteen year period. We examined subgroups and determined that antibiotic treatment was effective for older members of the population and for members with advanced precancerous gastric lesions at the beginning of the study, despite the fact that Helicobacter pylori is thought to act on early stages of gastric carcinogenesis. Thus antibiotic treatment can be applied broadly to prevent gastric cancer and need not be restricted to the young or to those with mild histopathology. This work was published in 2014. Inflammatory breast cancer (IBC) case-control study (00314) This case-control study includes approximately 250 IBC cases accrued at 5 centers in North Africa (1 center in Tunisia, 2 in Egypt, and 2 in Morocco). Two control groups are being included: 1) 250 non-IBC breast cancer cases and; 2) 250 visitor controls (excluding first-degree relatives) to randomly selected female inpatients (excluding those with breast, ovarian, endometrial, and nasopharyngeal cancer) in the study hospitals. The study involves the administration of a questionnaire, anthropometric measurements, saliva collectio